PacBio is THE long read sequencing technology. The Sequel IIe sequences 20KB with higher consensus accuracy than Illumina. No one can match that length with that accuracy.

The company is growing rapidly. Having crushed their numbers the past two years they’ve recently lured their CEO, COO, CCO, VP of Marketing, VP of Comm Ops, Director of Strat Accts, and other managers and salespersons from Illumina. These people left ILMN for PacBio because of the tremendous upside. They’re re-shaping and re-launching the company with far greater growth and success in mind. The financial community sees the opportunity: the stock is up 10X in the past year and Softbank recently invested $1B.

They’re on a rapidly accelerating success trajectory, developing new products, penetrating new markets and expanding. Their growth/success has created this expansion role to cover New England selling systems and consumables. The compensation is excellent and includes Restricted Stock Units which have actual value today (while stock options are only worth money when/if the stock rises).

Excellent company culture, great manager, outstanding technology and compensation.